TrovaGene NPM1 Technology Part of LabCorps AML Cancer Testing
TrovaGene Inc–formerly Xenomics Inc– developer of transrenal molecular diagnostics, announced that LabCorp and InVivoScribe Technologies have notified the company that they have begun laboratory testing services for the detection of NPM1 mutations for the diagnosis of acute myelogenous leukemia (AML).
Read More